Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 28;38(3):618-629.
doi: 10.1093/ndt/gfac158.

Multidisciplinary management of chronic refractory pain in autosomal dominant polycystic kidney disease

Affiliations

Multidisciplinary management of chronic refractory pain in autosomal dominant polycystic kidney disease

Franka van Luijk et al. Nephrol Dial Transplant. .

Abstract

Background: Chronic pain is often difficult to manage in autosomal dominant polycystic kidney disease (ADPKD) patients and sometimes even leads to nephrectomy. We analyzed the long-term efficacy of our innovative multidisciplinary protocol to treat chronic refractory pain that aims to preserve kidney function by applying among other sequential nerve blocks.

Methods: Patients were eligible if pain was present ≥3 months with a score of ≥50 on a visual analog scale (VAS) of 100, was negatively affecting quality of life and if there had been insufficient response to previous therapies, including opioid treatment. Treatment options were, in order, analgesics, cyst aspiration and fenestration, nerve blocks and nephrectomy.

Results: A total of 101 patients were assessed in our clinic (mean age 50 ± 11 years, 65.3% females). Eight patients were treated with medication, 6 by cyst aspiration or fenestration, 63 by nerve blocks and 6 received surgery as the first treatment option. Overall, 76.9% experienced a positive effect on pain complaints shortly after treatment. The VAS score was reduced from 60/100 to 20/100 (P < 0.001) and patients decreased their number of nonopioid and opioid analgesics significantly (P < 0.001, P = 0.01, respectively). A substantial number of the patients (n = 51) needed additional treatment. At the end of follow-up in only 13 patients (12.9%) was surgical intervention necessary: 11 nephrectomies (of which 10 were in patients already on kidney function replacement treatment), 1 liver transplantation and 1 partial hepatectomy. After a median follow-up of 4.5 years (interquartile range 2.5-5.3), 69.0% of the patients still had fewer pain complaints.

Conclusions: These data indicate that our multidisciplinary treatment protocol appears effective in reducing pain in the majority of patients with chronic refractory pain, while postponing or even avoiding in most patients surgical interventions such as nephrectomy in most patients.

Keywords: ADPKD; nephrectomy; nerve block; polycystic kidney disease.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
FIGURE 1:
FIGURE 1:
Treatment protocol for chronic refractory pain in ADPKD patients.
FIGURE 2:
FIGURE 2:
Flowchart of patients included for protocolized treatment of chronic refractory pain in ADPKD.
FIGURE 3:
FIGURE 3:
Effect of pain treatment on VAS score shortly after the intervention (2–6 weeks) and after longer-term follow-up. The red line indicates the median VAS score.
FIGURE 4:
FIGURE 4:
Effect of pain treatment on the use of opioids shortly after the intervention (2–6 weeks) and after longer-term follow-up. The red line indicates the mean DDD opioid use.

References

    1. Bajwa ZH, Sial KA, Malik ABet al. Pain patterns in patients with polycystic kidney disease. Kidney Int 2004; 66: 1561–1569 - PubMed
    1. Miskulin DC, Abebe KZ, Chapman ABet al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1–4: a cross-sectional study. Am J Kidney Dis 2014; 63: 214–226 - PMC - PubMed
    1. Torres VE, Harris PC, Pirson Y.. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287–1301 - PubMed
    1. Torres VE, Chapman AB, Devuyst Oet al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407–2418 - PMC - PubMed
    1. Oberdhan D, Cole JC, Krasa HBet al. Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-Life instrument. Am J Kidney Dis 2018; 71: 225–235 - PubMed

LinkOut - more resources